I am a
Home I AM A Search Login

Papers of the Week

2022 Sep 13

Eur J Clin Pharmacol

Daridorexant for the treatment of insomnia disorder: findings and implications.


Ribeiro Dos Santos J B, Ribeiro da Silva M R
Eur J Clin Pharmacol. 2022 Sep 13.
PMID: 36098753.


The involvement of the orexin system in the physiopathology of insomnia has been rapidly increasing in understanding. In this sense, daridorexant was the third orexin receptor antagonist approved by the FDA in January 2022. This review aims to summarize the chemistry, pharmacodynamics, pharmacokinetics, efficacy, safety, and tolerability profile of daridorexant for the treatment of insomnia disorder.